Cargando…

Inhibitors of Jumonji C domain-containing histone lysine demethylases overcome cisplatin and paclitaxel resistance in non-small cell lung cancer through APC/Cdh1-dependent degradation of CtIP and PAF15

The Jumonji C domain-containing family of histone lysine demethylases (Jumonji KDMs) have emerged as promising cancer therapy targets. These enzymes remove methyl groups from various histone lysines and, in turn, regulate processes including chromatin compaction, gene transcription, and DNA repair....

Descripción completa

Detalles Bibliográficos
Autores principales: Duan, Lei, Perez, Ricardo E., Calhoun, Sarah, Maki, Carl G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812751/
https://www.ncbi.nlm.nih.gov/pubmed/35100078
http://dx.doi.org/10.1080/15384047.2021.2020060
_version_ 1784644722009047040
author Duan, Lei
Perez, Ricardo E.
Calhoun, Sarah
Maki, Carl G.
author_facet Duan, Lei
Perez, Ricardo E.
Calhoun, Sarah
Maki, Carl G.
author_sort Duan, Lei
collection PubMed
description The Jumonji C domain-containing family of histone lysine demethylases (Jumonji KDMs) have emerged as promising cancer therapy targets. These enzymes remove methyl groups from various histone lysines and, in turn, regulate processes including chromatin compaction, gene transcription, and DNA repair. Small molecule inhibitors of Jumonji KDMs have shown promise in preclinical studies against non-small cell lung cancer (NSCLC) and other cancers. However, how these inhibitors influence cancer therapy responses and/or DNA repair is incompletely understood. In this study, we established cell line and PDX tumor model systems of cisplatin and paclitaxel-resistant NSCLC. We showed that resistant cells and tumors express high levels of Jumonji-KDMs. Knockdown of individual KDMs or treatment with a pan-Jumonji KDM inhibitor sensitized the cells and tumors to cisplatin and paclitaxel and blocked NSCLC in vivo tumor growth. Mechanistically, we found inhibition of Jumonji-KDMs triggers APC/Cdh1-dependent degradation of CtIP and PAF15, two DNA repair proteins that promote repair of cisplatin and paclitaxel-induced DNA lesions. Knockdown of CtIP and PAF15 sensitized resistant cells to cisplatin, indicating their degradation when Jumonji KDMs are inhibited contributes to cisplatin sensitivity. Our results support the idea that Jumonji-KDMs are a targetable barrier to effective therapy responses in NSCLC. Inhibition of Jumonji KDMs increases therapy (cisplatin/paclitaxel) sensitivity in NSCLC cells, at least in part, by promoting APC/Cdh1-dependent degradation of CtIP and PAF15.
format Online
Article
Text
id pubmed-8812751
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-88127512022-02-04 Inhibitors of Jumonji C domain-containing histone lysine demethylases overcome cisplatin and paclitaxel resistance in non-small cell lung cancer through APC/Cdh1-dependent degradation of CtIP and PAF15 Duan, Lei Perez, Ricardo E. Calhoun, Sarah Maki, Carl G. Cancer Biol Ther Research Paper The Jumonji C domain-containing family of histone lysine demethylases (Jumonji KDMs) have emerged as promising cancer therapy targets. These enzymes remove methyl groups from various histone lysines and, in turn, regulate processes including chromatin compaction, gene transcription, and DNA repair. Small molecule inhibitors of Jumonji KDMs have shown promise in preclinical studies against non-small cell lung cancer (NSCLC) and other cancers. However, how these inhibitors influence cancer therapy responses and/or DNA repair is incompletely understood. In this study, we established cell line and PDX tumor model systems of cisplatin and paclitaxel-resistant NSCLC. We showed that resistant cells and tumors express high levels of Jumonji-KDMs. Knockdown of individual KDMs or treatment with a pan-Jumonji KDM inhibitor sensitized the cells and tumors to cisplatin and paclitaxel and blocked NSCLC in vivo tumor growth. Mechanistically, we found inhibition of Jumonji-KDMs triggers APC/Cdh1-dependent degradation of CtIP and PAF15, two DNA repair proteins that promote repair of cisplatin and paclitaxel-induced DNA lesions. Knockdown of CtIP and PAF15 sensitized resistant cells to cisplatin, indicating their degradation when Jumonji KDMs are inhibited contributes to cisplatin sensitivity. Our results support the idea that Jumonji-KDMs are a targetable barrier to effective therapy responses in NSCLC. Inhibition of Jumonji KDMs increases therapy (cisplatin/paclitaxel) sensitivity in NSCLC cells, at least in part, by promoting APC/Cdh1-dependent degradation of CtIP and PAF15. Taylor & Francis 2022-01-31 /pmc/articles/PMC8812751/ /pubmed/35100078 http://dx.doi.org/10.1080/15384047.2021.2020060 Text en © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Paper
Duan, Lei
Perez, Ricardo E.
Calhoun, Sarah
Maki, Carl G.
Inhibitors of Jumonji C domain-containing histone lysine demethylases overcome cisplatin and paclitaxel resistance in non-small cell lung cancer through APC/Cdh1-dependent degradation of CtIP and PAF15
title Inhibitors of Jumonji C domain-containing histone lysine demethylases overcome cisplatin and paclitaxel resistance in non-small cell lung cancer through APC/Cdh1-dependent degradation of CtIP and PAF15
title_full Inhibitors of Jumonji C domain-containing histone lysine demethylases overcome cisplatin and paclitaxel resistance in non-small cell lung cancer through APC/Cdh1-dependent degradation of CtIP and PAF15
title_fullStr Inhibitors of Jumonji C domain-containing histone lysine demethylases overcome cisplatin and paclitaxel resistance in non-small cell lung cancer through APC/Cdh1-dependent degradation of CtIP and PAF15
title_full_unstemmed Inhibitors of Jumonji C domain-containing histone lysine demethylases overcome cisplatin and paclitaxel resistance in non-small cell lung cancer through APC/Cdh1-dependent degradation of CtIP and PAF15
title_short Inhibitors of Jumonji C domain-containing histone lysine demethylases overcome cisplatin and paclitaxel resistance in non-small cell lung cancer through APC/Cdh1-dependent degradation of CtIP and PAF15
title_sort inhibitors of jumonji c domain-containing histone lysine demethylases overcome cisplatin and paclitaxel resistance in non-small cell lung cancer through apc/cdh1-dependent degradation of ctip and paf15
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812751/
https://www.ncbi.nlm.nih.gov/pubmed/35100078
http://dx.doi.org/10.1080/15384047.2021.2020060
work_keys_str_mv AT duanlei inhibitorsofjumonjicdomaincontaininghistonelysinedemethylasesovercomecisplatinandpaclitaxelresistanceinnonsmallcelllungcancerthroughapccdh1dependentdegradationofctipandpaf15
AT perezricardoe inhibitorsofjumonjicdomaincontaininghistonelysinedemethylasesovercomecisplatinandpaclitaxelresistanceinnonsmallcelllungcancerthroughapccdh1dependentdegradationofctipandpaf15
AT calhounsarah inhibitorsofjumonjicdomaincontaininghistonelysinedemethylasesovercomecisplatinandpaclitaxelresistanceinnonsmallcelllungcancerthroughapccdh1dependentdegradationofctipandpaf15
AT makicarlg inhibitorsofjumonjicdomaincontaininghistonelysinedemethylasesovercomecisplatinandpaclitaxelresistanceinnonsmallcelllungcancerthroughapccdh1dependentdegradationofctipandpaf15